Alvotech: FDA Overhang Remains, Remaining Constructive, Initiate Hold (NASDAQ:ALVO)

Matteo Colombo Investment briefing The biosimilars drug market is forecast to expand at a geometric growth rate of ~18% from 2023—2028, garnishing immense capital inflows along the way. Alvotech (NASDAQ:ALVO) is firmly positioned within the biosimilars value chain and has the potential to unlock compelling value should it successfully convert its pipeline assets. To date,…

Read More